GlassScriptPhysician profile
Moshe Kincade
NPI 1407397086
$3,375.10
in general payments reported to CMS, 2019-2025
36 companies · $21.58 in 2025
The $21.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $1,324 · 2023: $794 · 2024: $809 · 2025: $21.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.71 | 2021-2024 | |
| Novo Nordisk INC | $352.04 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $320.98 | 2021-2024 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $255.82 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $249.36 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $218.91 | 2021-2024 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $185.62 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.02 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $135.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $98.27 | 2022-2024 | Breztri, Airsupra |
| Abbott Laboratories | $72.92 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.46 | 2022-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $65.16 | 2021-2024 | |
| Amarin Pharma, INC. | $61.83 | 2021-2022 | |
| Corium, LLC | $61.73 | 2023 | Adlarity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.70 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $41.97 | 2021-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $34.64 | 2023-2024 | Quviviq |
| Pfizer INC. | $27.68 | 2024 | |
| Biogen, INC. | $22.39 | 2022 | |
| Dynavax Technologies Corporation | $22.02 | 2023 | Heplisav-B |
| Dexcom, INC. | $21.58 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Nestle Healthcare Nutrition INC. | $20.10 | 2023 | |
| Eisai INC. | $19.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.79 | 2022 | |
| Ibsa Pharma INC. | $17.68 | 2023 | Tirosint, Licart |
| Axsome Therapeutics, INC. | $17.01 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.98 | 2022 | |
| Ardelyx, INC. | $15.88 | 2024 | Ibsrela |
| Currax Pharmaceuticals LLC | $14.70 | 2021 | |
| Esperion Therapeutics, INC. | $14.61 | 2024 | Nexletol |
| Mylan Specialty L.P. | $13.49 | 2023 | Yupelri |
| Exact Sciences Corporation | $13.18 | 2023 | Cologuard Collection Kit |
| Clarus Therapeutics INC. | $13.15 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Kincade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.